Manages OA. 1.2 Rheumatoid Arthritis (RA). ANDA 200562, held by Watson Labs Inc. Celecoxib.
As of Nov 15, 2026, ANDA 200562 (Celecoxib), held by Watson Labs Inc, was first approved by FDA on Feb 11, 2015, with 6 approved supplements and 0 published complete response letters.
Celecoxib capsules are indicated Celecoxib capsules are a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA. 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA. 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older. 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2015 | Original application | Approved | None posted |
| Aug 4, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 27, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 5, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 9, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 9, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 13, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 11, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters